Header Logo

Connection

ADEL K EL-NAGGAR to Treatment Outcome

Back to Details
This is a "connection" page, showing publications ADEL K EL-NAGGAR has written about Treatment Outcome.
ADEL K EL-NAGGAR
Connection Strength
0.366
Treatment Outcome
  1. Intestinal-type adenocarcinoma of the larynx: Report of a rare aggressive phenotype and discussion of histogenesis. Head Neck. 2014 May; 36(5):E44-7.
    View in: PubMed
    Score: 0.025
  2. Sinonasal neuroendocrine carcinoma: impact of differentiation status on response and outcome. Head Neck Oncol. 2011 Jul 27; 3:32.
    View in: PubMed
    Score: 0.022
  3. Collagenous myofibroblastic tumor of the mandible: case report of a unique locally aggressive neoplasm. Head Neck Pathol. 2010 Mar; 4(1):44-8.
    View in: PubMed
    Score: 0.019
  4. Meeting report--the NIDCR 2(nd) Salivary Gland Tumor Meeting, November 2008. Head Neck. 2009 Dec; 31(12):1542-3.
    View in: PubMed
    Score: 0.019
  5. Translocation t(6;14) as the sole chromosomal abnormality in adenoid cystic carcinoma of the base of tongue. Head Neck Pathol. 2007 Dec; 1(2):165-8.
    View in: PubMed
    Score: 0.017
  6. Epithelioid hemangioendothelioma of the head and neck: role of podoplanin in the differential diagnosis. Head Neck Pathol. 2008 Mar; 2(1):25-30.
    View in: PubMed
    Score: 0.017
  7. Outcomes in patients with adenoid cystic carcinoma of the lacrimal gland. Ophthalmic Plast Reconstr Surg. 2004 Jan; 20(1):22-6.
    View in: PubMed
    Score: 0.013
  8. Long-Term Update of NRG/RTOG 0522: A Randomized Phase 3 Trial of Concurrent Radiation and Cisplatin With or Without Cetuximab in Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2023 07 01; 116(3):533-543.
    View in: PubMed
    Score: 0.012
  9. Third window approach assisted middle meatal antrostomy: prospective cohort study of the two ports technique in management of hard to reach maxillary sinus pathology. J Laryngol Otol. 2020 Jul; 134(7):636-641.
    View in: PubMed
    Score: 0.010
  10. Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma. Head Neck. 2017 12; 39(12):2433-2443.
    View in: PubMed
    Score: 0.008
  11. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. J Clin Oncol. 2017 Jan 20; 35(3):352-360.
    View in: PubMed
    Score: 0.008
  12. Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522. Int J Radiat Oncol Biol Phys. 2017 03 15; 97(4):687-699.
    View in: PubMed
    Score: 0.008
  13. Long-term outcomes after multidisciplinary management of T3 laryngeal squamous cell carcinomas: Improved functional outcomes and survival with modern therapeutic approaches. Head Neck. 2016 12; 38(12):1739-1751.
    View in: PubMed
    Score: 0.008
  14. Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer. Clin Cancer Res. 2016 Sep 15; 22(18):4643-50.
    View in: PubMed
    Score: 0.007
  15. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol. 2016 Feb; 2(2):209-16.
    View in: PubMed
    Score: 0.007
  16. Phase II study of gefitinib in patients with advanced salivary gland cancers. Head Neck. 2015 May; 37(5):644-9.
    View in: PubMed
    Score: 0.007
  17. Rhabdomyosarcoma of the nose and paranasal sinuses in adults and children. Otolaryngol Head Neck Surg. 1995 Feb; 112(2):252-7.
    View in: PubMed
    Score: 0.007
  18. Long-term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: A 3-decade survey. Cancer. 2015 May 15; 121(10):1608-19.
    View in: PubMed
    Score: 0.007
  19. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014 Sep 20; 32(27):2940-50.
    View in: PubMed
    Score: 0.007
  20. Residual nodal disease in patients with advanced-stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: Association with locoregional recurrence, distant metastasis, and decreased survival. Head Neck. 2013 Oct; 35(10):1454-60.
    View in: PubMed
    Score: 0.006
  21. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell. 2012 Jun 12; 21(6):793-806.
    View in: PubMed
    Score: 0.006
  22. Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2012 Mar 01; 82(3):e367-74.
    View in: PubMed
    Score: 0.006
  23. Minor salivary gland malignancies in the pediatric population. Head Neck. 2012 Nov; 34(11):1648-51.
    View in: PubMed
    Score: 0.006
  24. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Mar 01; 18(5):1435-46.
    View in: PubMed
    Score: 0.006
  25. Phase II trial of induction chemotherapy followed by surgery for squamous cell carcinoma of the oral tongue in young adults. Head Neck. 2012 Sep; 34(9):1255-62.
    View in: PubMed
    Score: 0.005
  26. Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma. Head Neck. 2011 Feb; 33(2):189-98.
    View in: PubMed
    Score: 0.005
  27. Gene expression profiling predicts the development of oral cancer. Cancer Prev Res (Phila). 2011 Feb; 4(2):218-29.
    View in: PubMed
    Score: 0.005
  28. Compliance with quality assurance measures in patients treated for early oral tongue cancer. Cancer. 2010 Jul 15; 116(14):3408-16.
    View in: PubMed
    Score: 0.005
  29. Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure. Int J Radiat Oncol Biol Phys. 2010 Nov 15; 78(4):1005-10.
    View in: PubMed
    Score: 0.005
  30. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res. 2009 Nov 15; 15(22):7061-8.
    View in: PubMed
    Score: 0.005
  31. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila). 2009 Nov; 2(11):931-41.
    View in: PubMed
    Score: 0.005
  32. Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol. 2009 Apr 20; 27(12):1976-82.
    View in: PubMed
    Score: 0.005
  33. Effect of initial treatment on disease outcome for patients with submandibular gland carcinoma. Arch Otolaryngol Head Neck Surg. 2007 Jun; 133(6):546-50.
    View in: PubMed
    Score: 0.004
  34. Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res. 2006 May 15; 12(10):3109-14.
    View in: PubMed
    Score: 0.004
  35. Akt activation correlates with adverse outcome in tongue cancer. Cancer. 2005 Dec 01; 104(11):2430-6.
    View in: PubMed
    Score: 0.004
  36. Selective vs modified radical neck dissection and postoperative radiotherapy vs observation in the treatment of squamous cell carcinoma of the oral tongue. Arch Otolaryngol Head Neck Surg. 2005 Oct; 131(10):874-8.
    View in: PubMed
    Score: 0.004
  37. Survival impact of planned restaging and early surgical salvage following definitive chemoradiation for locally advanced squamous cell carcinomas of the oropharynx and hypopharynx. Am J Clin Oncol. 2005 Aug; 28(4):385-92.
    View in: PubMed
    Score: 0.004
  38. Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center. Head Neck. 2005 Feb; 27(2):138-49.
    View in: PubMed
    Score: 0.003
  39. Parathyroid carcinoma: a 22-year experience. Head Neck. 2004 Aug; 26(8):716-26.
    View in: PubMed
    Score: 0.003
  40. Radiation therapy for early-stage carcinoma of the oropharynx. Int J Radiat Oncol Biol Phys. 2004 Jul 01; 59(3):743-51.
    View in: PubMed
    Score: 0.003
  41. Malignant rhabdoid tumor arising from a pleomorphic adenoma. Ann Diagn Pathol. 2004 Jun; 8(3):156-61.
    View in: PubMed
    Score: 0.003
  42. Parathyroid carcinoma: evaluation and interdisciplinary management. Cancer. 2004 Mar 01; 100(5):900-5.
    View in: PubMed
    Score: 0.003
  43. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol. 2003 Dec 15; 21(24):4546-52.
    View in: PubMed
    Score: 0.003
  44. Radiotherapy in the management of giant cell tumor of bone. Int J Radiat Oncol Biol Phys. 2003 Sep 01; 57(1):158-65.
    View in: PubMed
    Score: 0.003
  45. Disparity in pathologic and clinical lymph node staging in oral tongue carcinoma. Implication for therapeutic decision making. Cancer. 2003 Aug 01; 98(3):508-15.
    View in: PubMed
    Score: 0.003
  46. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst. 2003 Feb 05; 95(3):198-205.
    View in: PubMed
    Score: 0.003
  47. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer. 2001 Nov 01; 92(9):2364-73.
    View in: PubMed
    Score: 0.003
  48. Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression. J Natl Cancer Inst. 2000 Jan 05; 92(1):69-73.
    View in: PubMed
    Score: 0.002
  49. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg. 1999 Oct; 125(10):1083-9.
    View in: PubMed
    Score: 0.002
  50. Histologically similar, synchronous or metachronous, lacrimal salivary-type and parotid gland tumors: A series of 11 cases. Head Neck. 1999 Sep; 21(6):512-6.
    View in: PubMed
    Score: 0.002
  51. Posterior approach for cervical intramedullary arteriovenous malformation with diffuse-type nidus. Report of three cases. J Neurosurg. 1999 Jul; 91(1 Suppl):105-11.
    View in: PubMed
    Score: 0.002
  52. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999 May 05; 91(9):763-71.
    View in: PubMed
    Score: 0.002
  53. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998 Jun; 16(6):2221-32.
    View in: PubMed
    Score: 0.002
  54. Radiation therapy for early stage (T1-T2) sarcomatoid carcinoma of true vocal cords: outcomes and patterns of failure. Laryngoscope. 1998 May; 108(5):760-3.
    View in: PubMed
    Score: 0.002
  55. Prognostic value of clinicopathological parameters in head and neck squamous cell carcinoma: a prospective analysis. Br J Cancer. 1996 Feb; 73(4):531-8.
    View in: PubMed
    Score: 0.002
  56. c-erbB-2/neu oncogene and Ki-67 analysis in the assessment of palatal salivary gland neoplasms. Otolaryngol Head Neck Surg. 1995 Mar; 112(3):391-8.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.